KR20210073525A - 튜불리신 및 이의 중간체의 제조를 위한 대체 방법들 - Google Patents

튜불리신 및 이의 중간체의 제조를 위한 대체 방법들 Download PDF

Info

Publication number
KR20210073525A
KR20210073525A KR1020217010157A KR20217010157A KR20210073525A KR 20210073525 A KR20210073525 A KR 20210073525A KR 1020217010157 A KR1020217010157 A KR 1020217010157A KR 20217010157 A KR20217010157 A KR 20217010157A KR 20210073525 A KR20210073525 A KR 20210073525A
Authority
KR
South Korea
Prior art keywords
moiety
optionally substituted
formula
compound
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217010157A
Other languages
English (en)
Korean (ko)
Inventor
쿤-리앙 우
칭우 진
웬델 더블데이
Original Assignee
씨젠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨젠 인크. filed Critical 씨젠 인크.
Publication of KR20210073525A publication Critical patent/KR20210073525A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217010157A 2018-09-07 2019-09-06 튜불리신 및 이의 중간체의 제조를 위한 대체 방법들 Withdrawn KR20210073525A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07
US62/728,639 2018-09-07
PCT/US2019/050023 WO2020051503A1 (en) 2018-09-07 2019-09-06 Alternative processes for the preparation of tubulysins and intermediates thereof

Publications (1)

Publication Number Publication Date
KR20210073525A true KR20210073525A (ko) 2021-06-18

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010157A Withdrawn KR20210073525A (ko) 2018-09-07 2019-09-06 튜불리신 및 이의 중간체의 제조를 위한 대체 방법들

Country Status (17)

Country Link
US (1) US20230002440A1 (https=)
EP (1) EP3847161A1 (https=)
JP (1) JP7511543B2 (https=)
KR (1) KR20210073525A (https=)
CN (1) CN112996778A (https=)
AU (1) AU2019336231A1 (https=)
BR (1) BR112021004317A2 (https=)
CA (1) CA3111149A1 (https=)
EA (1) EA202190699A1 (https=)
IL (1) IL281090A (https=)
MA (1) MA53550A (https=)
MX (1) MX2021002570A (https=)
SA (1) SA521421375B1 (https=)
SG (1) SG11202102126VA (https=)
TW (1) TWI825169B (https=)
UA (1) UA128730C2 (https=)
WO (1) WO2020051503A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867283A (zh) * 2020-12-23 2023-03-28 启德医药科技(苏州)有限公司 包含开环硫代琥珀酰亚胺基团、寡肽片段和手性部分的新型异构化合物
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138561A1 (en) * 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
KR20200051733A (ko) * 2017-09-08 2020-05-13 시애틀 지네틱스, 인크. 튜불리신 및 그 중간물의 제조 공정

Also Published As

Publication number Publication date
JP2021536475A (ja) 2021-12-27
JP7511543B2 (ja) 2024-07-05
IL281090A (en) 2021-04-29
MA53550A (fr) 2021-12-15
UA128730C2 (uk) 2024-10-09
WO2020051503A1 (en) 2020-03-12
TW202024043A (zh) 2020-07-01
TWI825169B (zh) 2023-12-11
CA3111149A1 (en) 2020-03-12
BR112021004317A2 (pt) 2021-05-25
CN112996778A (zh) 2021-06-18
SG11202102126VA (en) 2021-04-29
EA202190699A1 (ru) 2021-06-08
EP3847161A1 (en) 2021-07-14
US20230002440A1 (en) 2023-01-05
MX2021002570A (es) 2021-06-08
AU2019336231A1 (en) 2021-03-18
SA521421375B1 (ar) 2024-02-11

Similar Documents

Publication Publication Date Title
KR102626498B1 (ko) 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
AU2022275478A1 (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
KR20170053648A (ko) 삼차 아민-함유 약물 물질의 표적화된 전달
JP6957629B2 (ja) 非線状自壊性リンカーおよびそのコンジュゲート
JP2022518743A (ja) 抗体-薬物コンジュゲート用のグリコシド含有ペプチドリンカー
CA3206244A1 (en) Immunostimulatory compounds and conjugates
JP2023053386A (ja) チューブリシンおよびそれらの中間体の調製のためのプロセス
TW202000237A (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
CN116964076A (zh) 化合物或其盐、以及由它们得到的抗体
KR20210073525A (ko) 튜불리신 및 이의 중간체의 제조를 위한 대체 방법들
HK40045709A (en) Alternative processes for the preparation of tubulysins and intermediates thereof
HK40036588A (en) Process for the preparation of tubulysins and intermediates thereof
HK40009733A (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
NZ791149A (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202